Vantage logo

Covid-19 forces Lilly to hit the brakes

As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…

Company Events

Vantage logo

Lilly spends big on mirikizumab

With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.

Interviews

Vantage logo

Zynerba hopes to crack fragile X at last

The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.

Vantage Homepage